Thank you to our speakers, sponsors, and delegates who joined us in Boston for the 4th Wet AMD & Diabetic Eye Disease Drug Development Summit! If you are interested in the 2025 event, please get in touch at

Discovering Novel Retinal Vascular Models to Translate Neovascularization Targets Beyond Anti-VEGF into the Clinic

March 19 - 21, 2024 | Boston, MA

Accelerating Novel Retinal Vascular Target R&D into the Clinic

The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit returned to Boston this March to unite 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the only industry-dedicated forum to transform the potential of treatment of chronic, sight-threatening retinal vascular diseases to improve patient outcomes.     

Attendees joined the most comprehensive Wet AMD & Diabetic Eye Disease forum to: 

  • Hear data-driven case studies from industry experts from the likes of Bayer, Boehringer Ingelheim, Novartis and Genentech
  • Participate with the interactive expert panel discussion navigating the current anti-VEGF treatment
  • Meet and network with industry-based retinal vascular preclinical and clinical R&D scientists from Annexin Pharmaceuticals, OcuTerra Therapeutics, University of Southern California, Kodiak Sciences and more

18+ World-Class Pharma & Biotech Expert Speakers Included:

Past Companies in Attendance Included:

previously attending companies

2024 Partners:


Industry News:

“Great content from the most relevant players and very nice speakers from clinician and industry sides. Worth the time” 

Senior Leader, Clinical Program, Ophthalmology, Clinical Development & Medical Affairs, Boehringer Ingelheim


Other Events in the Ophthalmology & Sensory Series:


Download the 2024 Event Guide for More Information On:

  • Expert Speaker Faculty
  • Full 3-day Conference Agenda
  • Audience Breakdown
  • & more